Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Description
Compound Amino Acid is clinically used for patients with insufficient protein intake, malabsorption, and other amino acids that cannot meet the requirements of body metabolism. It was developed by Japan Ajinomoto Pharmaceutical Co., Ltd. At present, more than 20 categories of Compound Amino Acid injections have been approved in China. By 2020, in addition to Guangdong Litai Pharmaceutical Co., Ltd. in the Chinese Compound Amino Acid market, there are 34 companies, such as Guangzhou Green Cross Pharmaceutical Co., Ltd., Hubei Bantian Pharmaceutical Co., Ltd., Fujian Tianquan Pharmaceutical Co., Ltd., and Liaoning Haisco Pharmaceutical Co., Ltd.
According to Researcher analysis, the sales of Compound Amino Acids in the Chinese market have basically maintained a slow growth from 2016 to 2020, reaching about 1.53 billion in 2020, and the CAGR from 2016 to 2020 is about 1.8%. The main reason is that the clinical demand for Compound Amino acids is relatively stable.
CRI predicts that with the development of Compound Amino Acid categories from 2021 to 2025, the number of indications will increase so that sales and sales volume have potential for growth. Moreover, with the addition of new manufacturers in the Chinese Compound Amino Acid market, market competition will become increasingly fierce and sales will increase as prices fall.
Topics Covered:
-The impact of COVID-19 on China's Compound Amino Acid market
- Sales value of China's Compound Amino Acid 2016-2020
- Competitive landscape of China's Compound Amino Acid market
- Prices of Compound Amino Acid in China
- Prices of Compound Amino Acid in China by regions and manufacturers
- Analysis of factors affecting the development of China's Compound Amino Acid market
- Prospect of China's Compound Amino Acid market from 2021 to 2025
Compound Amino Acid is clinically used for patients with insufficient protein intake, malabsorption, and other amino acids that cannot meet the requirements of body metabolism. It was developed by Japan Ajinomoto Pharmaceutical Co., Ltd. At present, more than 20 categories of Compound Amino Acid injections have been approved in China. By 2020, in addition to Guangdong Litai Pharmaceutical Co., Ltd. in the Chinese Compound Amino Acid market, there are 34 companies, such as Guangzhou Green Cross Pharmaceutical Co., Ltd., Hubei Bantian Pharmaceutical Co., Ltd., Fujian Tianquan Pharmaceutical Co., Ltd., and Liaoning Haisco Pharmaceutical Co., Ltd.
According to Researcher analysis, the sales of Compound Amino Acids in the Chinese market have basically maintained a slow growth from 2016 to 2020, reaching about 1.53 billion in 2020, and the CAGR from 2016 to 2020 is about 1.8%. The main reason is that the clinical demand for Compound Amino acids is relatively stable.
CRI predicts that with the development of Compound Amino Acid categories from 2021 to 2025, the number of indications will increase so that sales and sales volume have potential for growth. Moreover, with the addition of new manufacturers in the Chinese Compound Amino Acid market, market competition will become increasingly fierce and sales will increase as prices fall.
Topics Covered:
-The impact of COVID-19 on China's Compound Amino Acid market
- Sales value of China's Compound Amino Acid 2016-2020
- Competitive landscape of China's Compound Amino Acid market
- Prices of Compound Amino Acid in China
- Prices of Compound Amino Acid in China by regions and manufacturers
- Analysis of factors affecting the development of China's Compound Amino Acid market
- Prospect of China's Compound Amino Acid market from 2021 to 2025
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
